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7552 | Chem. Sci., 2017, 8, 7552–7559cted nanoparticle assemblies
based on single amino acid peptide mutations
activate cellular uptake and decrease tumor
volume†
Shang Li,‡a Rongfeng Zou,‡ad Yaoquan Tu,d Junchen Wu*ab
and Markita P. Landry *bc
Peptide drugs have been difficult to translate into effective therapies due to their low in vivo stability. Here, we
report a strategy to develop peptide-based therapeutic nanoparticles by screening a peptide library differing
by single-site amino acid mutations of lysine-modified cholesterol. Certain cholesterol-modified peptides are
found to promote and stabilize peptide a-helix formation, resulting in selectively cell-permeable peptides.
One cholesterol-modified peptide self-assembles into stable nanoparticles with considerable a-helix
propensity stabilized by intermolecular van der Waals interactions between inter-peptide cholesterol
molecules, and shows 68.3% stability after incubation with serum for 16 h. The nanoparticles in turn
interact with cell membrane cholesterols that are disproportionately present in cancer cell membranes,
inducing lipid raft-mediated endocytosis and cancer cell death. Our results introduce a strategy to identify
peptide nanoparticles that can effectively reduce tumor volumes when administered to in in vivo mice
models. Our results also provide a simple platform for developing peptide-based anticancer drugs.Introduction
De novo design of peptide therapeutic agents requires both cell
permeability and in vivo stability. a-helices are secondary struc-
tures found in nearly every native protein, and as peptides, have
been shown to effectively internalize into cells.1 However, a-
helical peptides alone are susceptible to proteolysis, and lack
structural stability provided when these domains are found
within a protein. As such, three principal challenges currently
limit targeted intracellular delivery of anticancer functional
peptides to cancer cells and in vivo: (I) individual peptides must
adopt and maintain a robust a-helical conformation to maintain
therapeutic efficacy. (II) Individual peptides must not be suscep-
tible to proteolysis when administered in vivo, (III) cancer cell
membranes exhibit reduced uidity due to theirInstitute of Fine Chemicals, School of
ast China University of Science and
il: jcwu@ecust.edu.cn
ar Engineering, University of California
lifornia 94720, USA. E-mail: landry@
ciences (qb3), University of California-
ogy, School of Biotechnology, KTH Royal
, Sweden
tion (ESI) available. See DOI:
is work.disproportionately high cholesterol content, thus anticancer
peptidesmust penetrate through the viscous cholesterol-rich lipid
bilayers of cancer cell membranes.2 Therefore, if a-helical
peptides can be designed at the molecular level to have in vivo
stability and target internalization through cholesterol-rich cell
membranes, a-helical peptides could be used as anticancer
drugs.3 However, to date, the exact mechanism by which a poly-
peptide chains fold into a secondary structure remains elusive.
Therefore, designing peptide or protein from primary sequence
that will adopt a stable a-helical secondary structure, one that is
protected against proteolysis under in vivo circulation, remains
difficult.
Several approaches have been explored to stabilize a-helical
therapeutic peptides by covalently linking i and either i + 4 or i +
7 amino-acid residues with amide bonds,4 hydrocarbon bonds
connected by olen metathesis,5 and triazoles connected
between azides and alkynes.6 While these methods effectively
reduce the conformational exibility of peptide, covalent
linkers require harsh reaction conditions not easily amenable to
peptide and protein substrates, and also require the peptide to
have two reactive groups in the backbone.7
We instead wish to exploit biological self-assembly and non-
covalent interactions inherent to protein folding as a design
strategy for a-helical peptide therapy development. We seek to
maximize the a-helicity and in vivo stability by inducing
hydrogen bonding, electrostatic interactions, and hydrophobic
interactions between peptide units.8 Increasing electrostaticThis journal is © The Royal Society of Chemistry 2017
Fig. 1 (a) Sequences of HAL-2, HAL-B, HAL-C and HAL-D. Heptad
positions are shown in italics. (b) Helical wheel diagram of the HAL-C
sequence. Z letter refers to a substituted heptad f position in HAL-2
(orientation as in (a)). Energy-minimized a-helical structure of HAL-C
(side view) and the conceptual nanoparticle formed by HAL-C. The
gold balls refer to the cholesterol structure. The cartoon helices of
HAL-C formed nanoparticles via the interaction between cholesterol
molecules. (c) A cholesterol structure unit is modified in the lysine side
(Z).
Fig. 2 (a) Zeta potentials of HAL-2, HAL-B, HAL-C and HAL-D in TBS
(10, 20 and 30 mM, pH 7.4). (b) Helix propensity of HAL-2, HAL-C and
HAL-D in TBS (pH 7.4) as a function of peptide concentration.
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View Article Onlineinteractions between peptides may induce intra-peptide nano-
particle self-assembly, whereby the resulting nanoparticle could
protect individual a-helix monomers, much like the stability of
a-helices is protected when folded into a larger protein struc-
ture. Lastly, introducing cholesterol along the a-helical peptide
can favour peptide interaction with the disproportionate
number of cholesterol units on cancer cell membranes. For this
reason, we choose to leverage the overabundance of cell surface
cholesterol on cancer cells to favour interactions between our
therapeutic peptides and cancer cells.
We seek to identify cholesterol-modied a-helical peptides
that can self-assemble into in vivo stable nanoparticles. To this
end, we developed a small peptide library (N ¼ 4) where each
peptide differs by a single-site amino acid mutation of lysine-
modied cholesterol. By introducing cholesterol units, we aim
to increase the hydrophobic microenvironment of the peptide
to (I) stabilize the a-helicity of peptides and (II) induce spon-
taneous self-assembly of peptides into nanostructures. The
stable nanostructures could activate the cell's lipid ra-
mediated endocytosis pathway in the cholesterol-rich domain
of cancer cell membranes, thereby maximizing interactions
between therapeutic peptides and cancer cells.8
Based on the above considerations, we chose the base
sequence of our peptide as halictines-2 (ref. 9) (HAL-2, Gly–Lys–
Trp–Met–Ser–Leu–Leu–Lys–His–Ile–Leu–Lys–NH2), from which
to introduce cholesterol point mutations. HAL-2 is an antimi-
crobial peptide, but has low potency against cancer cells.10
Thus, we seek to increase HAL-2 anticancer efficacy both in vitro
and in vivo by introducing lysine cholesterol modications on
the base HAL-2 peptide sequence.
Results and discussion
Our peptide design is based on the “a–b–c–d–e–f–g” heptad
repeat rule, and accompanying folding and self-assembly
simulations, where the hydrophobic (c, d, f, g) and hydro-
philic (a, b, e) faces of the HAL-2 peptide drive a-helical
folding.11 We selectively replace one residue, denoted ‘Z’, on
either hydrophilic or hydrophobic peptide face to generate three
peptides, HAL-B and HAL-C, and HAL-D respectively (Fig. 1), to
introduce cholesterol at each site with the intention of under-
standing the consequences of cholesterol incorporation at these
sites, and their subsequent impact on the self-assembly and
secondary structure of the resulting peptide nanoparticle. The
Fmoc-protected lysine side chain-connected cholesterol unit
was synthesized as previously described.12 Subsequently, HAL-2,
HAL-B, HAL-C and HAL-D were synthesized by Fmoc-based
solid-phase synthesis. Amino acids coupled on a Rink amide
resin were cleaved from the resin, and protecting groups were
removed (Fig. S1–S4, ESI†).
Peptides with greater positive surface charge are known to
have a higher binding affinity toward the negatively charged
cancer cell membrane, and thus show enhanced anticancer
efficacy.13 Moreover, particles with greater positive surface
experience strong charge repulsions in solvents, which can
promote self-stabilization among monomers as in colloidal
dispersions. The zeta-potential (z) of 10 mMHAL-2, HAL-B, HAL-This journal is © The Royal Society of Chemistry 2017C and HAL-D in TBS were measured to be 3.4  0.1 mV, 5.5 
0.2 mV, 24.5  0.1 mV, and 18.7  1.1 mV, respectively (Fig. 2).
We note that the zeta-potential of HAL-C (z: 24.5  0.1 mV) is
the highest among all the peptides. We tested the
concentration-dependent zeta potential of HAL-2, HAL-B, HAL-
C and HAL-D. All peptides showed very slight differences in
zeta-potential that do not scale as a function of concentration
(Fig. 2a). The concentration-independent zeta potential of HAL
peptides, particularly HAL-C and HAL-D, suggests that the
formation of self-assembled HAL-C and HAL-D structures can
be achieved in biologically-relevant media such as TBS.
Furthermore, the relatively high zeta-potential of HAL-C
increases inter-molecular interactions between HAL-C
peptides, and cholesterol subunits further promote nano-
particle formation via hydrophobic interactions, which help
stabilize the self-assembled HAL-C nanoparticles. An MBCD
titration experiment, which binds to and shields cholesterol,Chem. Sci., 2017, 8, 7552–7559 | 7553
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View Article Onlineshows that decreasing cholesterol–cholesterol interactions
affects the zeta-potential of the nanoparticle solution (Fig. S5,
ESI†), which further indicates that the hydrophobic interactions
between cholesterol units can help stabilize the nanoparticles.
Conformational stability of peptides in TBS were further
evaluated by circular dichroism (CD) spectroscopy over a 5 to 30
mM concentration range. HAL-C and HAL-D display standard a-
helical bands with two negative peaks at 208 and 222 nm, while
HAL-2 remains a random coil structure as indicated by a nega-
tive CD band at 205 nm. HAL-B shows sheet-like structures. The
helix propensity14 of HAL-2, HAL-C, HAL-D are 10%, 90%, and
80%, respectively (Fig. 2b and S6, ESI†). Repeating CD
measurements of HAL-2 (20 mM), and comparing to CD
measurements of HAL-B (20 mM), HAL-C (20 mM) and HAL-D
(20 mM) in TBS with pH of 4.0, 7.4, and 8.5 further conrm
conformational stability of the helices under a range of pH
values, and the random coil structure of HAL-2 (Fig. S7, ESI†).
These results suggest that site-specic cholesterol incorpora-
tion at a peptide hydrophobic site drives the peptide to adopt
a stable a-helical secondary structure, facilitated by the
increased hydrophobic microenvironment – a structure absent
in the unsubstituted cholesterol-free HAL-2 peptide.
We performed dynamic light scattering (DLS) measurements
of all peptides to estimate the hydrodynamic radii of the
resulting self-assemblies. DLS measurements reveal that 10 mM
HAL-B, HAL-C and HAL-D peptides self-assemble into nano-
particles with a mean diameter of 87 nm, 92 nm, and 97 nm,
respectively, compared with HAL-2 nanoparticles that have
a mean diameter of 47 nm (Fig. 3c, S8 and Table S1, ESI†) in
TBS. By increasing the peptide concentration from 10 to 30 mM,
the sizes of the nanoparticles formed by HAL-2 (90 nm), HAL-B
(125 nm), HAL-C (121 nm) and HAL-D (104 nm) also increased.
To conrm that peptides self-assemble into nanoparticles, we
performed atomic force microscopy (AFM) and transmission
electron microscopy (TEM) imaging to investigate the
morphology and size polydispersity of the self-assembled
peptides (10 mM) in TBS. Interestingly, AFM (Fig. 3a) and TEMFig. 3 (a) AFM and (b) TEM images of HAL-C (10 mM) in TBS (pH 7.4). (c)
DLS of HAL-C (10 mM) in TBS (pH 7.4). (d) HPLC spectra of peptides,
serum, and peptides incubated with mouse serum taken at 1 h, 8 h and
16 h at 37 C.
7554 | Chem. Sci., 2017, 8, 7552–7559(Fig. 3b) images show that only HAL-C (10 mM) self-assembles
into stable branching nanoparticles with a sharply-distributed
average diameter of 100 nm and a height of 10–20 nm. In
contrast, we observe that HAL-2 (10 mM) forms a broad distri-
bution of colloidal spherical particles with diameters ranging
from tens of nanometers to a fewmicrons, and heights of 50 nm
in TEM and AFM images (Fig. S9a and S10a, ESI†). HAL-B and
HAL-D both self-assemble into nanoparticles, with nanometer-
scale diameters ranging from tens to hundreds of nanometers
(Fig. S9b–d and S10b–d, ESI†), and heights of 10–20 nm. Thus, it
is likely that HAL-C nanostructures self-assemble via inter-
cholesterol subunit interactions of individual HAL-C peptides,
which is absent in the original HAL-2 sequence. We stress that
the a-helix folding of HAL-C is driven by the asymmetry
(hydrophobic and hydrophilic) of the peptide's two faces. This
folding pattern will drive a random coil structure to adopt
a helical structure (Fig. 1b).15 AFM and TEM characterization of
HAL-C shows these peptides subsequently self-assemble to
form stable branched nanoparticles with a narrow diameter
distribution. MD simulations show that the self-assemblies
formed by HAL-2 are not stable, whereas both HAL-B and
HAL-D can self-assemble into one stable nanoparticle, while
HAL-C forms two small nanoparticles (Fig. S11, ESI†). MD
simulations also reveal that the lysine residues lie on the surface
of the nanoparticle self-assemblies of HAL-B, HAL-C and HAL-
D, which promote charge repulsions between the nano-
particles. We observe some hydrophobic residues lying on the
surface of self-assemblies, which can drive the self-assemblies
to further aggregate. HAL-B showed the highest hydrophobic
residue exposure (ca. 44%, Fig. S12, ESI†), HAL-C and HAL-D
self-assemblies have slightly lower hydrophobic residue
surface exposures (ca. 35% and ca. 33.5%, respectively, Fig. S12,
ESI†). Based on the highly positive zeta potential of HAL-C and
HAL-D nanoparticles, and the hydrophobic residue exposure
revealed by MD simulations, it is likely that charge repulsions
and hydrophobic interactions drive the nal morphology of the
self-assemblies. Conversely, the relatively small zeta potential of
HAL-B and HAL-D promotes their self-assembly into spherical
nanoparticles. HAL-C forms stable branched nanoparticles with
a tightly-distributed distribution of nanoparticle diameters,
likely due to the relatively strong charge repulsions between the
nanoparticles. The stability of the peptides was examined by
a serum test and subsequent HPLC analysis. Results show that
HAL-C is the most stable peptide, with 68.3% remaining intact
aer incubation with serum for 16 h (Fig. 3d, S13 and Table S2,
ESI†). HAL-B and HAL-D showed 54.8% and 60.7% intactness,
respectively. HAL-2 is the least stable peptide, with only 11.2%
of the peptide remaining intact aer 16 h of incubation in
serum.
The anticancer activity of all the peptides was tested by an
MTT assay. As shown in Fig. 4a and b, for SKOV-3 ovarian cancer
cells, cholesterol-modied peptides HAL-B (IC50¼ 24.6 0.1 mM),
HAL-C (IC50 ¼ 12.7  0.1 mM) and HAL-D (IC50 ¼ 16.2  0.1 mM)
have low IC50 values compared to that of unmodied HAL-2
(IC50 ¼ 54.1  0.5 mM). For A549 adenocarcinomic human alve-
olar basal epithelial cells, IC50 values also show that modied
peptides exhibit signicantly enhanced cytotoxicity towardsThis journal is © The Royal Society of Chemistry 2017
Fig. 4 (a) Dose-response curves of HAL-2, HAL-B, HAL-C and HAL-D
for SKOV-3 cells. The data are presented as mean SD (n¼ 5). (b) IC50
values of SKOV-3 cells incubated with the four peptide nanoparticles.
(**P < 0.01, ***P < 0.001). (c) Live/dead assays of SKOV-3 cells incu-
bated with HAL-2 (12 mM) and HAL-C (12 mM) imaged with CLSM.
Fig. 5 (a) CLSM images of SKOV-3 cells cultured for 1 h with the HAL-
2/NR complex (15/0.2 mM), and HAL-C/NR complex at various
concentrations (5/0.06, 10/0.12 and 15/0.2 mM), (NR, red), (DAPI, blue).
(b) The fold-increase values of MFI for SKOV-3 cells treated with
different concentrations of HAL-2/NR and HAL-C/NR complex (2/
0.025, 4/0.05 and 8/0.1 mM) in 5A media, respectively. (c) Dose-
response curves of HAL-2 and HAL-C in the presence of 100 mL
DiBAC4 (5) for the membrane potential effects in SKOV-3 cells at
various concentrations (0–15 mM). Data are normalized to DiBAC4 (5)
fluorescence responses and presented as mean  SD (n $ 3, ***P <
Edge Article Chemical Science
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View Article Onlinecancer cells as compared to the native HAL-2 peptide (Fig. S14,
ESI†), providing high therapeutic efficacy toward cholesterol-rich
and negatively charged A549 cells.16 Due to the superior stability
and cellular activity of the HAL-C peptide nanoparticles, we chose
HAL-C for further experiments, and HAL-2 as a control. Live/dead
cell staining assays of HAL-2 and HAL-C dosed SKOV-3 cells also
shows that HAL-C is more potent than HAL-2.17 Fig. 4c shows the
results of live/dead cell assays with SYTO-9/PI, in which live cells
uorescence green, and dead cells uorescence red. We nd that
HAL-C induces death of SKOV-3 cells, shown by a 50% green and
50% red uorescence cell count. In contrast, an equal concen-
tration of HAL-2 does not induce SKOV-3 cell death, shown by
a 97% green and 3% red uorescence cell count.
Furthermore, to examine the stability of the self-assembled
HAL-C nanoparticles, the critical nanoparticle forming
concentration (CNC) was probed with Nile Red (NR) dye stain-
ing.18 The CNC of HAL-C was found to be 7 mM in TBS, sug-
gesting that at and above 7 mM, HAL-C can self-assemble and
encapsulate NR dye. Under the same conditions, HAL-2 does
not reach a discernible CNC, suggesting it does not form
nanoparticles and can therefore not encapsulate NR dye
(Fig. S15, ESI†). The stable nanoparticles formed by HAL-C
encapsulating Nile Red (NR) dye were then used to study the
binding and penetration of NR-loaded HAL-C nanoparticles
into SKOV-3 cells. SKOV-3 cells were incubated with HAL-2/NR
(15/0.2 mM) and HAL-C/NR (5/0.06, 10/0.12 and 15/0.2 mM) for
1 h at 37 C in McCoy's 5A media. Co-localization uorescence
imaging was used to visualize NR dye relative to the cell, and
DAPI staining allowed localization of NR dye relative to the cell
nucleus. Cell images were obtained by confocal laser scanning
microscopy (CLSM) (Fig. 5a). SKOV-3 cells treated with HAL-C/
NR exhibit strong red uorescence, with the NR uorescenceThis journal is © The Royal Society of Chemistry 2017intensity increasing with increasing HAL-C/NR concentration.
In contrast, we nd no NR dye uorescence in SKOV-3 cells
treated with HAL-2/NR. Flow cytometric assays (Fig. 5b and S16,
ESI†) also revealed a concentration-dependence of NR uores-
cent signals when added with, and thus encapsulated by HAL-C,
but not when the same dye was incubated with HAL-2. To
further investigate the mechanism of cell penetration, cell
membrane potentials were tested by monitoring the uores-
cence intensity of the anionic cell membrane marker DiBAC4
(5).19 As shown in Fig. 5c, SKOV-3 cells incubated with 0 to 16
mM HAL-2 show no change in membrane potential. However,
for SKOV-3 cells incubated with 0 to 15 mM HAL-C, the uo-
rescence intensity of the membrane increases with increasing
HAL-C concentration. Our results suggest HAL-C induces
depolarization of the SKOV-3 cell membrane.
To probe the pathway of cellular uptake and death by HAL-C,
we quantied the delivery efficiency of HAL-C in SKOV-3 cells
with various endocytosis inhibitors, including amiloride (AM,
macropinocytosis inhibitor), chlorpromazine (CPZ, clathrin-
mediated endocytosis inhibitor) and methyl-beta cyclodextrin
(MBCD, a lipid ra-mediated endocytosis inhibitor), with
concentrations of inhibitors previously reported in the litera-
ture.20 We observe that the intracellular delivery efficiency of
HAL-C was signicantly decreased only by MBCD treatment
(Fig. 6a), suggesting that a lipid ra-mediated endocytosis
pathway is the primary intracellular delivery mechanism of
HAL-C nanoparticles. Based on MTT assays, MBCD showed no
signicant effects toward SKOV-3 cells at the tested concentra-
tions within the 40 min incubation period, and we found that
AM and CPZ slightly decrease SKOV-3 cell viability by 20% and
38%, respectively, due to inhibition of clathrin-mediated
endocytosis and micropinocytosis, which inherently decrease0.001).
Chem. Sci., 2017, 8, 7552–7559 | 7555
Fig. 6 (a) CLSM images of SKOV-3 cell pre-treated with AM, CPZ or
MBCD at 37 C for 40 min, rinsed, and subsequently incubated with
HAL-C/NR (10 mM) at 37 C for 1 h. (b) SKOV-3 cells stained with
Phalloidin-iFluor™ 488 (F-actin, green), DAPI (nuclei, blue), or tubulin
tracker (red) after incubation with HAL-2 (10 mM) and HAL-C (10 mM)
for 1 h.
Fig. 7 Evaluating therapeutic efficacy of HAL-C in vivo. (a) Time
dependent relative tumor volume. (b) The tumor inhibitory rates (TIRs)
of the tumors after 14 days treatment (**P < 0.01 and ***P < 0.001).
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View Article Onlinecellular metabolic activity (Fig. S17, ESI†). However, all cells
assayed remained structurally intact.
We observe that the intracellular delivery of HAL-C is
inhibited only in MBCD-treated cells (Fig. 6a), suggesting that
a lipid ra-mediated endocytosis pathway is the primary intra-
cellular delivery mechanism of HAL-C nanoparticles. The
potency of HAL-C toward MBCD treated cells is lower than for
untreated cells (Fig. S18, ESI†), which indicates that choles-
terols on the cell membrane play an import role in cellular
uptake of HAL-C, and that HAL-Cmost likely targets cholesterol-
rich areas of the cell membrane. Lipid-ra mediated endocy-
tosis is driven by cholesterol-dependent invagination of glyco-
lipid ras, thus supporting our design strategy of targeting
cholesterol-rich cancer cell membranes with cholesterol-
modied HAL peptides. To further examine the mechanism of
HAL-induced cell death, we probed the structure and integrity
of the SKOV-3 cellular cytoskeleton upon exposure to HAL-2 and
HAL-C. We examined the changes of F-actin and microtubule
structure upon exposure of SKOV-3 cells exposed to 10 mM of
HAL-2 or HAL-C.21 As shown in Fig. 6b, SKOV-3 cells treated with
HAL-2 have similar F-actin andmicrotubule network features as7556 | Chem. Sci., 2017, 8, 7552–7559untreated SKOV-3 cells, but SKOV-3 cells treated with HAL-C
mainly exhibit short, truncated actin laments and condensed
microtubules surrounding the plasma membrane. The HAL-C
induced disruption of SKOV-3 cellular microtubule networks
indicates that HAL-C nanoparticles disrupt the dynamics of F-
actin and promotes the formation of apoptotic microtubule
networks resulting in cell death.22
Next, the therapeutic efficacy of HAL-C was evaluated in vivo.
Tumor mice models bearing subcutaneous SKOV-3-xenogras
were dosed by intravenous injections of HAL-C (5 mg kg1)
and HAL-2 (5 mg kg1) every 2 days. A PBS injection was used as
a negative control. Aer two weeks of treatment, the tumor
volume of mice treated with HAL-C decreases by over 66%,
compared to the tumor volume of mice treated with HAL-2
(Fig. 7a and S19a, ESI†). We did not observe signicant
changes in mouse body mass for the mice in our study
(Fig. S19b, ESI†). The tumor inhibitory rates (TIRs) were calcu-
lated from the excised mouse tumor weights. Compared with
the PBS injection cohort, the TIRs of HAL-C and HAL-2 were
62.6  0.6%, and 32.9  1.3%, respectively (Fig. 7b). Thus, HAL-
C is a promising in vivo tumor therapy, owing to the cholesterol
modication that distinguishes the mode of activity of HAL-C
from the native HAL-2 peptide, as well as the HAL-C self-
assembly nanoscale size, which could leverage the enhanced
permeability and retention (EPR) effect to target the tumor.23
Conclusions
In summary, we report a novel strategy to tailor natural poly-
peptides for anticancer therapy. Herein, we accomplish tumor-
cell targeting based on single amino acid cholesterol derivatives
of HAL-2 peptide. We demonstrate the strong inhibitory
potency of one particular cholesterol modied HAL-2 poly-
peptide, HAL-C, which self-assembles to form nanoparticles.
HAL-C peptide nanoparticles, but not the HAL-2 peptide coun-
terpart, show strong potency to induce cell death in SKOV-3
cells. Our results suggest that natural polypeptides can be
systematically point-modied with cholesterol to identify
effective anti-tumor drug candidates. The cholesterol inserted
into the HAL-2 base peptide sequence signicantly increases
the a-helicity of the peptide and also the surface positive charge
of the resulting self-assembled HAL-C nanoparticles, which
greatly increase their stability in serum. Accompanying molec-
ular dynamics simulations and cellular imaging studies suggest
the enhanced cellular uptake of the modied peptide can be
attributed to activation of a lipid ra-mediated endocytosis
pathway that disrupts the cellular microtubule network. The
self-assemblies show promise of targeting a tumor in an in vivo
mouse model. Most importantly, this work paves the way
towards further study of cholesterol-modied natural poly-
peptides for cancer therapy.
Experimental section
Zeta potential measurement
The zeta potential of peptides was measured by a Nano-ZS
(Zatasizer, Malvern) instrument. Samples of HAL-2, HAL-B,This journal is © The Royal Society of Chemistry 2017
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View Article OnlineHAL-C and HAL-D solution (10, 20, 30 mM) were dissolved in
TBS (50 mM Tris, 50 mM NaCl, pH 7.4, 25 C). All data were
corrected by subtracting the value tested for a blank scan of the
buffer system. Results were presented as mean  SD (n ¼ 3).Circular dichroism (CD) analysis
Circular dichroism spectra of peptides were acquired under in
50 mM TBS (50 mM Tris, 50 mM NaCl, pH 7.4, 25 C). The
circular dichroism spectra of HAL-2, HAL-B, HAL-C and HAL-D
were measured at 25 C with a J-820 spectropolarimeter (Jasco,
Tokyo, Japan) equipped with a rectangular quartz cell with
a path length of 0.3 cm. Spectra were recorded at a scanning
speed of 10 nm min1 from 190 nm to 260 nm. An average of
three scans were collected for HAL-2, HAL-B, HAL-C and HAL-D.
The CD spectra were then converted to mean residue ellip-
ticity using the following equation:24
[q]obs ¼ [q]222  1000/cln
where [q]obs is mean residue ellipticity [deg cm
2 dmol1], [q]222
is the observed ellipticity corrected for the buffer at a given
wavelength of 222 nm [mdeg], c is the peptide concentration
[mM], l is the path length [mm] and n is the number of amino
acids.
The average helical content of the peptide was calculated
according to the formula:25
% helix ¼ 100([q]obs  [q]0222)/[q]100222
where, [q]0222¼ estimated ellipticity of a peptide with 0% helicity
(1000 deg cm2 dmol1) and [q]100222 ¼ estimated ellipticity of
a 100% helical peptide (36 500 deg cm2 dmol1).Atomic force microscopy (AFM)
Images were recorded by a Veeco/DI atomic force microscope.
HAL-2, HAL-B, HAL-C and HAL-D were dissolved in TBS (50 mM
Tris, 50 mM NaCl, pH 7.4, 25 C). A drop of the HAL-2, HAL-B,
HAL-C and HAL-D solution (10 mM) was placed on freshly
cleaved mica for 30 s and allowed to dry at room temperature.
The sample was then analyzed in tapping mode.Transmission electron microscopy (TEM)
High-resolution images of HAL-2, HAL-B, HAL-C and HAL-D
were acquired using TEM. HAL-2, HAL-B, HAL-C and HAL-D
were dissolved in TBS (50 mM Tris, 50 mM NaCl, pH 7.4,
25 C). A drop of the HAL-2, HAL-B, HAL-C and HAL-D solution
(10 mM) was placed on a carbon-coated grid with holes, stained
with sodium phosphotungstate (2.0 wt% aqueous solutions),
and dried at room temperature. TEM characterization was
performed using a JEM-2100 electronmicroscope (JEOL, Japan).Dynamic light scattering (DLS)
The DLS experiments were determined by Nano-ZS (zatasizer,
Malvern) instrument, and starting solutions were ltered prior
to use. Samples of HAL-2, HAL-B, HAL-C and HAL-D solution (10This journal is © The Royal Society of Chemistry 2017and 30 mM) in TBS (50 mM Tris, 50 mMNaCl, pH 7.4, and 25 C)
in a total sample volume of 1.0 mL, respectively.
MTT assays
The cytotoxicity was tested using an MTT assay. SKOV-3 and
A549 cells growing in log phase were seeded into 96-well cell-
culture plates at a cell density of 5  104 cells per well. The
cells were incubated for 12 h at 37 C under 5% CO2. Solutions
of HAL-2 (100.0 mL per well), HAL-B (100.0 mL per well), HAL-C
(100.0 mL per well) or HAL-D (100.0 mL per well) at concentra-
tions of 1, 2, 4, 8, 16, 32, 64, 128 mM inMcCoy's 5A mediumwere
added to the wells of the treatment group, and 100.0 mL of
McCoy's 5A medium was added as negative control group. The
cells were incubated for 24 h at 37 C under 5% CO2. A
combined solution of 5 mg mL1 MTT/PBS (10 mL per well) was
added to each well of the 96-well plate assay, and the cells were
incubated for an additional 4 hours. Formazan extraction was
performed with DMSO and quantied colorimetrically using
a Synergy H4 Hybrid Microplate reader (Biotek, USA), which was
used to measure the OD 490 nm (absorbance value). The
following formula was used to calculate the viability of cell
growth: viability (%) ¼ (mean of absorbance value of treatment
group-blank/mean absorbance value of control-blank)  100
(MTT was purchased from Sigma-Aldrich).
Live/dead assay
SKOV-3 cells were seeded in a 35 mm Petri dish with a glass
cover slide and allowed to adhere overnight at 37 C under 5%
CO2. Cells were then incubated with HAL-2 or HAL-C for 24 h.
Cells were stained with the live/dead assay reagents (SYTO-9/PI)
and then incubated at 37 C for 15min. Aer washing with 1mL
phosphate buffered saline (PBS), cells were observed by
confocal laser scanning microscopy (CLSM; Nikon A1, Japan,
60 oil-immersion objective lens). Green channel for SYTO-9:
excitation: 488 nm, emission collected: 500–550 nm; red
channel for PI: excitation: 561 nm, emission collected: 570–
620 nm (SYTO-9/PI were purchased from Invitrogen).
Stability studies of peptides in the serum
A 1.5 mL mixture consisting of 30 mL mouse serum, 750 mL of
peptides (1 mg mL1) and 1470 mL of digestion buffer (pH 8.2,
50 mM Tris, 20 mM CaCl2) was incubated at 37 C for 16 h.
Peptides treated with digestion buffer served as controls. Aliquots
of 400 mL were withdrawn from the mixture and quenched with
400 mL of 1% triuoroacetic acid (TFA) solution at 1 h, 8 h and
16 h. The quenched solution was analysed by reverse-phase high
performance liquid chromatography (RP-HPLC).
Critical nanoparticle-forming concentration (CNC) with Nile
Red
A Nile Red solution (250 nM) was prepared in THF. HAL-2 or
HAL-C were dissolved at 1 mM in PBS (pH of 7.4), then the
solutions were diluted serially to obtain peptide concentrations
in the range of 1.0 to 35 mM. 2 mL of Nile Red solution was added
to each sample and aged for 10 h to ensure full peptideChem. Sci., 2017, 8, 7552–7559 | 7557
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View Article Onlinedisassembly at concentrations below the critical nanoparticle
formation concentration. Fluorescence-emission spectra (exci-
tation 550 nm) were recorded for an emission range between
560 and 700 nm. The maximum intensity and respective wave-
length at maximum intensity were both represented as a func-
tion of the logarithm of the peptide concentration. At
concentrations close to critical nanoparticle formation
concentration, we observed a sharp increase in uorescence
intensity.
Encapsulation of Nile Red
Briey, a stock solution of Nile Red (100 mM) was prepared in
CHCl3, HAL-2, or HAL-C was dissolved at 400 mM in aqueous
solution. While being stirred, 50 mL of Nile Red stock solution
was slowly added to the HAL-2 or HAL-C solution (1 mL). This
solution was then stirred for 3 h and aged for 24 h at room
temperature in a closed container to allow vesicles to form. The
solution was freeze-dried and then dissolved in aqueous solu-
tion (1 mL) and ltered through 0.45 mm membrane to remove
insoluble Nile Red.
Confocal laser scanning microscopy (CLSM) images
SKOV-3 cells were seeded in a 35 mm Petri dish with a glass cover
slide and allowed to adhere overnight. Aer washing the cells with
PBS (pH 7.4), the SKOV-3 cells were incubated with HAL-2/NR or
HAL-C/NR in McCoy's 5A for 40 min, respectively. Cells imaging
was then carried out aer washing with PBS (pH 7.4, 1 mL  5
times). Cell uorescence images were obtained with a confocal
laser scanning microscope (Nikon A1, Japan, 60 oil-immersion
objective lens). Red channel for Nile red: excitation: 561 nm,
emission collected: 570–620 nm; blue channel for DAPI: excita-
tion: 405 nm, emission collected: 425–475 nm.
Flow cytometry
The quantitative evaluation of cellular uptake of peptide nano-
particles was performed by ow cytometry (BD FACSAria). SKOV-3
cells were seeded in 6-well plates (106 cells per well) and cultured
in McCoy's 5A (1 mL) for 12 h at 37 C under 5% CO2. Aer that,
HAL-2/NR or HAL-C/NR dispersed in McCoy's 5A (1 mL) with
different peptide concentrations ranging from 2 mM to 8 mM
added to the cells, with incubation at 37 C for 40 min. The
medium was then removed, and the cells were washed with PBS
(1 mL  5 times). Aerward, the cells were digested with trypsin
and collected in centrifuge tubes by centrifugation. The super-
natant was discarded and PBS was added to suspend the cells for
examination by ow cytometry. Cells untreated with HAL-2/NR
and HAL-C/NR were used as negative controls. The uorescence
scan was performed with 5.0 104 cells. The fold-increase values
of mean uorescence intensity (MFI) were calculated by the
following equation: the fold increases values of MFI ¼ MFI of
treatment group  MFI of control/MFI of control.
Membrane potential
Membrane potential changes in SKOV-3 cells were measured
using the membrane potential-sensitive dye, DiBAC4 (5). Stock7558 | Chem. Sci., 2017, 8, 7552–7559solutions of DiBAC4 (5) were prepared in dimethylsulfoxide and
diluted in buffer before use. SKOV-3 cells were plated at 5  104
cells/100 mL in black/clear 96-well plate for experiments, aer
incubation for 24 h at 37 C under 5% CO2. Subsequently,
growth medium was removed, and PBS (100.0 mL per well)
containing 1 mM DiBAC4 (5) was added to the wells and incu-
bated for 40 min at 37 C. HAL-2 or HAL-C solutions were then
added to the plate to achieve nal peptide concentrations of 0,
2.5, 5, 7.5, 10, 12.5, 15 mM for further 30 min incubation at
37 C. The cell culture plate was then transferred to the
temperature-controlled (37 C) compartment of the Synergy H4
Hybrid Microplate reader (Biotek, USA) where DiBAC4 (5) uo-
rescence was measured from the 96 wells at excitation and
emission wavelengths of 590 and 625 nm, respectively. (DiBAC4
(5) was purchased from AmyJet Scientic Inc).
Tubulin staining
SKOV-3 cells were seeded in a 35 mm Petri dish with a glass
cover slide and allowed to adhere overnight at 37 C under 5%
CO2. The culture medium was then removed and replaced with
fresh McCoy's 5A medium containing HAL-2 (10 mM) or HAL-C
(10 mM) for 1 h. Aer the medium was removed and the cells
were washed with PBS (1 mL 3 times), 1 mL of PBS containing
4 mL staining solution was added for 1 h. The cells were then
washed with PBS (1 mL  3 times) before imaging. Cell uo-
rescence images were obtained with a confocal laser scanning
microscope. Green channel for Tubulin-Trakcer Red: excitation:
561 nm, emission collected: 570–620 nm; blue channel for
DAPI: excitation: 405 nm, emission collected: 425–475 nm
(Tubulin-Trakcer Red were purchased from Beyotime
Biotechnology).
Delivery mechanisms of HAL-2 and HAL-C
SKOV-3 cells were seeded in a 35 mm Petri dish with a glass
cover slide and allowed to adhere overnight at 37 C under 5%
CO2. Aer washing the cells with PBS (1 mL  1 times), the
SKOV-3 cells were incubated with PBS containing methyl-beta
cyclodextrin (MBCD, 10 mM), chlorpromazine (CPZ, 20 mM) or
amiloride (AM, 5 mM) for 40 min at 37 C. Aer washing the
cells with PBS at the 40 minute time-point (1 mL  3 times)
1 mL of fresh McCoy's 5A medium containing HAL-2 (10 mM) or
HAL-C (10 mM) was added to the cells and le to incubate for
30 min. Cell imaging was then carried out aer washing the
cells with PBS (1 mL  5 times). Cell uorescence images were
obtained with a confocal laser scanning microscope. Red
channel for Nile Red: excitation: 561 nm, emission collected:
570–620 nm; blue channel for DAPI: excitation: 405 nm, emis-
sion collected: 425–475 nm. (Methyl-beta cyclodextrin, chlor-
promazine and amiloride were purchased from J&K Scientic
Ltd.).
In vivo experiments
All animal experiments were performed in agreement with
guidelines set by the Institutional Animal Care and Use
Committee, and conform to the guidelines for the care and use
of laboratory animals. SKOV-3 cells were washed with PBS (pHThis journal is © The Royal Society of Chemistry 2017
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View Article Online7.4), and harvested using 0.25% Trypsin/EDTA (Sigma). Aer
centrifugation, the harvested cells were then suspended in PBS
(pH 7.4). Four week-old (approximately 15 g) female BALB/c
nude mice (Shanghai Slac Laboratory Animal Co. Ltd., China)
were implanted subcutaneously on the right ank with 2
million SKOV-3 cells in 0.1 mL PBS (pH 7.4), and tumors
developed within four weeks.
In vivo antitumor studies: when the tumors reached a mean
volume of 50 mm3 aer inoculation with SKOV-3 cells, the mice
were randomly separated into three groups (n ¼ 3/group): (1)
negative control (PBS); (2) HAL-2; (3) HAL-C. The mice received
intravenous peptide injections at 5 mg kg1 in 0.1 mL PBS every
2 days for 14 days. During therapy, the tumor volumes and body
weights were measured every two days. Length and width of
tumors were measured individually using a vernier caliper.
Tumor volumes were calculated using the following formula:
tumor volume ¼ length  width2  0.5. The mice were sacri-
ced 16 days aer the treatments according to institutional
guidelines. Tumors were resected, weighed, xed in formalin
and then embedded in paraffin. The therapeutic efficacy of the
treatment was evaluated by the tumor inhibition rate (TIR). This
was calculated using the following equation: TIR ¼ 100% 
(mean tumor weight of control group  mean tumor weight of
experimental group)/mean tumor weight of control group.
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